Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs.
Journal
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
ISSN: 1179-190X
Titre abrégé: BioDrugs
Pays: New Zealand
ID NLM: 9705305
Informations de publication
Date de publication:
20 Apr 2024
20 Apr 2024
Historique:
accepted:
30
03
2024
medline:
21
4
2024
pubmed:
21
4
2024
entrez:
20
4
2024
Statut:
aheadofprint
Résumé
An ambitious reform of the early access (EA) process was set up in July 2021 in France, aiming to simplify procedures and accelerate access to innovative drugs. This study analyzes the characteristics of oncology drug approvals through the EA process and its impact on real-life data for oncology patients. The number and characteristics of EA demands concerning oncology drugs submitted to the National Health Authority (HAS, Haute Autorité de Santé) were reviewed until 31 December 2022. A longitudinal retrospective study on patients treated with an EA oncology drug between 1 January 2019 and 31 December 2022 was also performed using the French nationwide claims database (Systeme National des Données de Santé [SNDS]) to assess the impact of the reform on the number of indications and patients, and the costs. Among 110 published decisions, the HAS granted 88 (80%) EA indications within 70 days of assessment on average, including 46 (52%) in oncology (67% in solid tumors and 33% in hematological malignancies). Approved indications were mostly supported by randomized phase III trials (67%), whereas refused EA relied more on non-randomized (57%) trials. Overall survival was the primary endpoint of 28% of EA approvals versus none of denied EAs. In the SNDS data, the annual number of patients with cancer treated with an EA drug increased from 3137 patients in 2019 to 18,341 in 2022 (+ 484%), whereas the number of indications rose from 12 to 62, mainly in oncohematology (n = 17), lung (n = 12), digestive (n = 9) and breast cancer (n = 9). Reimbursement costs for EA treatments surged from €42 to €526 million (+ 1159%). The French EA reform contributed to enabling rapid access to innovations in a wide range of indications for oncology patients. However, the findings highlight ongoing challenges in financial sustainability, warranting continued evaluation and adjustments.
Sections du résumé
BACKGROUND
BACKGROUND
An ambitious reform of the early access (EA) process was set up in July 2021 in France, aiming to simplify procedures and accelerate access to innovative drugs.
OBJECTIVE
OBJECTIVE
This study analyzes the characteristics of oncology drug approvals through the EA process and its impact on real-life data for oncology patients.
METHODS
METHODS
The number and characteristics of EA demands concerning oncology drugs submitted to the National Health Authority (HAS, Haute Autorité de Santé) were reviewed until 31 December 2022. A longitudinal retrospective study on patients treated with an EA oncology drug between 1 January 2019 and 31 December 2022 was also performed using the French nationwide claims database (Systeme National des Données de Santé [SNDS]) to assess the impact of the reform on the number of indications and patients, and the costs.
RESULTS
RESULTS
Among 110 published decisions, the HAS granted 88 (80%) EA indications within 70 days of assessment on average, including 46 (52%) in oncology (67% in solid tumors and 33% in hematological malignancies). Approved indications were mostly supported by randomized phase III trials (67%), whereas refused EA relied more on non-randomized (57%) trials. Overall survival was the primary endpoint of 28% of EA approvals versus none of denied EAs. In the SNDS data, the annual number of patients with cancer treated with an EA drug increased from 3137 patients in 2019 to 18,341 in 2022 (+ 484%), whereas the number of indications rose from 12 to 62, mainly in oncohematology (n = 17), lung (n = 12), digestive (n = 9) and breast cancer (n = 9). Reimbursement costs for EA treatments surged from €42 to €526 million (+ 1159%).
CONCLUSION
CONCLUSIONS
The French EA reform contributed to enabling rapid access to innovations in a wide range of indications for oncology patients. However, the findings highlight ongoing challenges in financial sustainability, warranting continued evaluation and adjustments.
Identifiants
pubmed: 38643301
doi: 10.1007/s40259-024-00658-1
pii: 10.1007/s40259-024-00658-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
European Commission. European Cancer Information System [cited 2023 Jul 31]. https://ecis.jrc.ec.europa.eu/ .
International Agency for Research on Cancer. Cancer Tomorrow [cited 2023 Jul 31]. https://gco.iarc.fr/tomorrow/en .
Polkowska M, Ekk-Cierniakowski P, Czepielewska E, Wysoczański W, Matusewicz W, Kozłowska-Wojciechowska M. Survival of melanoma patients treated with novel drugs: retrospective analysis of real-world data. J Cancer Res Clin Oncol. 2017;143:2087–94.
doi: 10.1007/s00432-017-2453-z
pubmed: 28608286
Assié J-B, Corre R, Levra MG, Calvet CY, Gaudin A-F, Grumberg V, et al. Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study). Ther Adv Med Oncol. 2020;12:1758835920967237.
doi: 10.1177/1758835920967237
pubmed: 33403011
pmcid: 7745546
Newton M, Stoddart K, Travaglio M, Troein P. EFPIA Patients W.A.I.T. Indicator 2022 Survey.
Europe’s Beating Cancer Plan. European Commission; 2021 [cited 2023 Jan 23]. https://primarysources.brillonline.com/browse/human-rights-documents-online/communication-from-the-commission-to-the-european-parliament-and-the-council;hrdhrd46790058 .
Tarantola A, Otto MH, Armeni P, Costa F, Malandrini F, Jommi C. Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case. J Pharm Policy Pract. 2023;16:67.
doi: 10.1186/s40545-023-00570-z
pubmed: 37198599
pmcid: 10193685
European Medicines Agency. Support for early access. Amsterdam: European Medicines Agency; 2018 [cited 2023 Aug 1]. https://www.ema.europa.eu/en/human-regulatory/overview/support-early-access .
France’s New Framework for Regulating Off-Label Drug Use | NEJM [cited 2023 Jul 31]. https://doi.org/10.1056/NEJMp1208347 .
DGOS; DGS. Autorisation d’accès précoce, autorisation d’accès compassionnel et cadre de prescription compassionnelle. Ministère de la Santé et de la Prévention. 2023 [cited 2023 Aug 3]. https://sante.gouv.fr/soins-et-maladies/medicaments/professionnels-de-sante/autorisation-de-mise-sur-le-marche/article/autorisation-d-acces-precoce-autorisation-d-acces-compassionnel-et-cadre-de .
French National Health Insurance. The proposals of the French National Health Insurance for 2024. 2023 [cited 2023 Jul 31]. https://assurance-maladie.ameli.fr/etudes-et-donnees/2023-rapport-propositions-pour-2024-charges-produits .
Autorisation d’accès précoce, autorisation d’accès compassionnel et cadre de prescription compassionnelle. Ministry of Health and Prevention. 2023 [cited 2023 Jan 10]. https://solidarites-sante.gouv.fr/soins-et-maladies/medicaments/professionnels-de-sante/autorisation-de-mise-sur-le-marche/article/autorisation-d-acces-precoce-autorisation-d-acces-compassionnel-et-cadre-de .
Early access to medicinal products. Haute Autorité de Santé [cited 2023 Feb 2]. https://www.has-sante.fr/jcms/r_1500918/en/early-access-to-medicinal-products .
Martinalbo J, Bowen D, Camarero J, Chapelin M, Démolis P, Foggi P, et al. Early market access of cancer drugs in the EU. Ann Oncol. 2016;27:96–105.
doi: 10.1093/annonc/mdv506
pubmed: 26487583
Pham FY-V, Jacquet E, Taleb A, Monard A, Kerouani-Lafaye G, Turcry F, et al. Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019. Int J Cancer. 2022;151:1345–54.
doi: 10.1002/ijc.34129
pubmed: 35603979
pmcid: 9540593
Jacquet E, Kerouani-Lafaye G, Grude F, Goncalves S, Lorence A, Turcry F, et al. Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years. Eur J Cancer. 2021;149:82–90.
doi: 10.1016/j.ejca.2021.03.008
pubmed: 33838392
Avis et décisions sur les médicaments. Haute Autorité de Santé [cited 2023 Aug 1]. https://www.has-sante.fr/jcms/p_3281266/fr/avis-et-decisions-sur-les-medicaments .
WHOCC - ATC/DDD Index [cited 2023 Aug 4]. https://www.whocc.no/atc_ddd_index/ .
Scailteux L-M, Droitcourt C, Balusson F, Nowak E, Kerbrat S, Dupuy A, et al. French administrative health care database (SNDS): the value of its enrichment. Therapies. 2019;74:215–23.
doi: 10.1016/j.therap.2018.09.072
HAS. Transparency Committee doctrine. 2020.
Early access to medicinal products. Haute Autorité de Santé [cited 2023 Oct 17]. https://www.has-sante.fr/jcms/r_1500918/en/early-access-to-medicinal-products .
Subbiah V, Wirth LJ, Kurzrock R, Pazdur R, Beaver JA, Singh H, et al. Accelerated approvals hit the target in precision oncology. Nat Med. 2022;28:1976–9.
doi: 10.1038/s41591-022-01984-z
pubmed: 36192554
Trends in the approval of cancer therapies by the FDA in the twenty-first century | Nature Reviews Drug Discovery [cited 2023 Jul 27]. https://www.nature.com/articles/s41573-023-00723-4 .
LEEM. Bilan économique 2021 des entreprises du médicament—Edition 2022 [cited 2023 Aug 4]. https://www.leem.org/publication/bilan-economique-2021-des-entreprises-du-medicament-edition-2022 .
Agrawal S, Arora S, Amiri-Kordestani L, de Claro RA, Fashoyin-Aje L, Gormley N, et al. Use of single-arm trials for US Food and Drug Administration Drug Approval in Oncology, 2002–2021. JAMA Oncol. 2023;9(2):266–72. https://doi.org/10.1001/jamaoncol.2022.5985 .
doi: 10.1001/jamaoncol.2022.5985
pubmed: 36580315
Fashoyin-Aje LA, Mehta GU, Beaver JA, Pazdur R. The on- and off-ramps of oncology accelerated approval. N Engl J Med. 2022;387:1439–42.
doi: 10.1056/NEJMp2208954
pubmed: 36129992
Beaver JA, Pazdur R. “Dangling” accelerated approvals in oncology. N Engl J Med. 2021;384: e68.
doi: 10.1056/NEJMp2104846
pubmed: 33882220
Mushti SL, Mulkey F, Sridhara R. Evaluation of overall response rate and progression-free survival as potential surrogate endpoints for overall survival in immunotherapy trials. Clin Cancer Res. 2018;24:2268–75.
doi: 10.1158/1078-0432.CCR-17-1902
pubmed: 29326281
Renne M, Maquin G, Rosant D, Villiet M, Seron A. Feedback from a university hospital one year after the “simplified” reform of early and expanded access programme: a growing complexity for health professionals. J Pharm Clin. 2022;41:149–57.